Pharmacogenetics of ophthalmic topical β-blockers

Personalized Medicine

Volumn 5, Issue 4, 2008, Pages 377-385

  Sidjanin, Duska J ^a   McCarty, Catherine A ^b   Patchett, Richard ^b   Smith, Edward ^a   Wilke, Russell A ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b MARSHFIELD CLINIC   (United States)

Author keywords

adrenergic receptor; blocker; CYP2D6; Glaucoma; IOP; Polymorphisms; Timolol

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; CYTOCHROME P450 2D6; EYE DROPS; LATANOPROST; METOPROLOL; PROSTAGLANDIN DERIVATIVE; TIMOLOL MALEATE;

BLINDNESS; BRADYCARDIA; BRONCHOSPASM; BURNING SENSATION; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; EYE SURGERY; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLAUCOMA; HEALTH CARE COST; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HUMAN; HYPOTENSION; INDIVIDUALIZATION; INTRAOCULAR HYPERTENSION; LOW LEVEL LASER THERAPY; MOLECULAR MECHANICS; PHARMACOGENETICS; PREVALENCE; PRIORITY JOURNAL; PUNCTATE KERATITIS; RESPIRATORY FAILURE; REVIEW; RISK FACTOR; SIDE EFFECT; TEAR FLOW; TRABECULOPLASTY; UNSPECIFIED SIDE EFFECT;

EID: 50549086113     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.5.4.377     Document Type: Review

References (65)

1. Resnikoff S, Pascolini D, Etya'ale D et al.: Global data on visual impairment in the year 2002. Bull. World Health Organ. 82, 844-851 (2002).
2. Friedman DS, Wolfs C, O'Colmain BJ et al.: Eye Diseases Prevalence Research Group. Prevalence of open-angle glaucoma among adults in the United States. Arch. Ophthalmol. 122, 532-538 (2004).
3. Foster PJ: The epidemiology of primary angle closure and associated glaucomatous optic neuropathy. Semin. Ophthalmol. 17, 50-58 (2002).
4. Sowka J: New thoughts on normal tension glaucoma. Optometry 76, 600-608 (2005).
5. Alward WL: Medical management of glaucoma. N. Engl. J. Med. 29, 1298-1307 (1998).
6. Stoilov I, Akarsu AN, Sarfarazi M: Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucome (buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum. Mol. Genet. 6, 641-647 (1997).
7. Idrees F, Vaideanu D, Fraser SG, Sowden JC, Khaw PT: A review of anterior segment dysgeneses. Surv. Ophthalmol. 51, 213-231 (2006).
8. Stone EM, Fingert JH, Alward WLM et al.: Identification of a gene that causes primary open angle glaucoma. Science 275, 668-670 (1997).
9. Suzuki Y, Shirato S, Taniguchi F, Ohara K, Nishimaki K, Ohta S: Mutations in the TIGRgene in familial primary open-angle glaucoma in Japan. Am. J. Hum. Genet. 61, 1202-1204 (1997).
10. Wiggs JL, Vollrath D: Molecular and clinical evaluation of a patient hemizygous for TIGR/MYOC. Arch. Ophthalmol. 119, 1674-1678 (2001).
11. Rezaie T, Child A, Hitchings R et al.: Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science 295, 1077-1079 (2002).
12. Monemi S, Spaeth G, DaSilva A et al.: Identification of a novel adult-onset primary open-angle glaucoma (POAG) gene on 5q22.1. Hum. Mol. Genet. 14, 725-733 (2005).
13. Schulzer M, Drance SM, Douglas GR: A comparison of treated and untreated glaucoma suspects. Ophthalmology 98, 301-307 (1991).
14. Fleming C, Whitlock EP, Beil T, Smit B, Harris RP: Screening for primary open-angle glaucoma in the primary care setting: an update for the US Preventive Services Task Force. Ann. Fam. Med. 3, 167-170 (2005).
15. American Academy of Ophthalmology: Preferred Practice Pattern for Primary Open-Angle Glaucoma. AAO, CA, USA (2005).
16. Papadopoulos M, Khaw PT: Advances in the management of paediatric glaucoma. Eye 21, 1319-1325 (2007).
17. Enyedi LB, Freedman SF: Latanoprost for the treatment of pediatric glaucoma. Surv. Ophthalmol. 47, S129-S132 (2002).
18. Shin J, Johnson JA: Pharmacogenetics of β-blockers. Pharmacotherapy 27, 874-887 (2007).
19. Hoyng PF, van Beek LM: Pharmacological therapy for glaucoma: a review. Drugs 59, 411-434 (2000).
20. Coakes RL, Brubaker RF: The mechanism of timolol in lowering intraocular pressure in the normal eye. Arch. Ophthalmol. 96, 2045-2048 (1978).
21. Zimmerman TJ, Harbin R, Pett M, Kaufman HE: Timolol and facility of outflow. Invest. Ophthalmol. Vis. Sci. 16, 623-624 (1977).
22. Sonntag JR, Brindley GO, Shields MB: Effect of timolol therapy on outflow facility Invest. Ophthalmol. Vis. Sci. 17, 293-296 (1978).
23. Zimmerman TJ, Boger WP: The β-adrenergic blocking agents and the treatment of glaucoma. Surv. Ophthalmol. 23, 347-362 (1979).
24. Higginbotham EJ, Schuman JS, Goldberg I et al.: Bimatoprost study groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch. Ophthalmol. 120, 1286-1293 (2002).
25. Netland PA, Landry T, Sullivan EK et al.: Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 132, 472-484 (2002).
26. McLaren NC, Moroi SE: Clinical implications of pharmacogenetics for glaucoma therapeutics. Pharmacogenomics J. 3, 197-201 (2003).
27. Nieminen T, Lehtimaki T, Maenpaa J, Ropo A, Uusitalo H, Kahonen M: Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand. J. Clin. Lab. Invest. 67, 237-245 (2007).
28. Leier CV, Baker ND, Weber PA: Cardiovascular effects of ophthalmic timolol. Ann. Intern. Med. 104, 197-199 (1986).
29. Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN: Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am. J. Ophthalmol. 15, 606-611 (1986).
30. McMahon CD, Shaffer RN, Hoskins HD, Hetherington J: Adverse effects experienced by patients taking timolol. Am. J. Ophthalmol. 88, 736-738 (1979).
31. van Buskirk EM: Adverse reactions from timolol administration. Ophthalmology. 87, 447-450 (1980).
32. Bonomi L, Zavarise G, Noya E, Michieletto S: Effects of timolol maleate on tear flow in human eyes. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. 213, 19-22 (1980).
33. Fiscella RG, Green A, Patuszynski DH, Wilensky J: Medical therapy cost considerations for glaucoma. Am. J. Ophthalmol. 136, 18-25 (2003).
34. Stewart WC, Sine C, Cate E, Minno GE, Hunt H: Daily cost of β-adrenergic therapy. Arch. Ophthalmol. 115, 853-856 (1987).
35. Sorensen SJ, Abel SR: Comparison of ocular β-blockers. Ann. Pharmacother. 30, 43-54 (1996).
36. Eichelbaum M, Ingelman-Sundberg M, Evans WE: Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119-137 (2006).
37. Evans WE, Relling MV: Moving towards individualized medicine with pharmacogenomics. Nature 429, 464-468 (2004).
38. Wax MB, Molinoff PB: Distribution and properties of β-adrenergic receptors in human iris-ciliary body. Invest. Ophthalmol. Vis. Sci. 28, 420-430 (1987).
39. Taylor MRG: Pharmacogenetics of the human β-adrenergic receptors. Pharmacogenomics J. 7, 29-37 (2007).
40. Moore JD, Mason DA, Green SA, Hsu J, Liggett SB: Racial differences in the frequencies of cardiac β(1)-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C. Hum. Mutat. 14, 271 (1999).
41. Mason DA, Moore JD, Green SA, Liggett SB: A gain-of-function polymorphism in a G-protein coupling domain of the human β1-adrenergic receptor. J. Biol. Chem. 274, 12670-12674 (1999).
42. Levin MC, Marullo S, Muntaner O, Andersson B, Magnusson Y: The myocardium-protective Gly-49 variant of the β1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J. Biol. Chem. 277, 30429-30435 (2002).
43. Green SA, Turki J, Innis M, Liggett SB: Amino-terminal polymorphisms of the human β 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33, 9414-9419 (1994).
44. Mialet Perez J, Rathz DA, Petrashevskaya NN et al.: β 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat. Med. 9, 1300-1305 (2003).
45. Iwai C, Akita H, Kanazawa K et al.: Arg389Gly polymorphism of the human β1-adrenergic receptor in patients with nonfatal acute myocardial infarction. Am. Heart J. 146, 106-109 (2003).
46. Turki J, Pak J, Green SA, Martin RJ, Liggett SB: Genetic polymorphisms of the β 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly 16 correlates with the nocturnal phenotype. J. Clin. Invest. 95, 1635-1641 (1995).
47. Timmermann B, Mo R, Luft FC et al.: β-2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study. Kidney Int. 53, 1455-1460 (1998).
48. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA: β2-adrenergic receptor genotype and survival among patients receiving β-blocker therapy after an acute coronary syndrome. JAMA 294, 1526-1533 (2005).
49. del Moral R, Lopez ME, Nunez MI et al.: Interactions between radiotherapy and endocrine therapy in breast cancer. Endocr. Relat. Cancer 9, 197-205 (2002).
50. Terra SG, McGorray SP, Wu R et al.: Association between β-adrenergic receptor polymorphisms and their G-protein-coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE study. Int. J. Obes. 29, 746-754 (2005).
51. Miyaki K, Sutani S, Kikuchi H et al.: Increased risk of obesity resulting from the interaction between high energy intake and the Trp64Arg polymorphism of the β3-adrenergic receptor gene in healthy Japanese men. J. Epidemiol. 15, 203-210 (2005).
52. Hao K, Peng S, Xing H et al.: β(3) adrenergic receptor polymorphism and obesity-related phenotypes in hypertensive patients. Obes. Res. 12, 125-130 (2004).
53. Schwartz SG, Puckett BJ, Allen RC, Castillo IG, Leffler CT: β1-adrenergic receptor polymorphisms and clinical efficacy of betaxolol hydrochloride in normal volunteers. Ophthalmology 112, 2131-2136 (2005).
54. Nieminen T, Uusitalo H, Maenpaa J et al.: Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. Eur. J. Clin. Pharmacol. 61, 811-819 (2005).
55. McCarty CA, Wilke RA, Giampietro PF, Wesbrook S, Caldwell MD: Marshfield Clinic Personalized Medicine Research Project (PMRP): design, methods and recruitment for a large, population-based biobank. Personalized Medicine 2, 49-79 (2005).
56. McCarty CA, Burmester JK, Mukesh BN, Patchett RB, Wilke RA: Pressure response to topical β-blockers is associated with an ADRB2 SNP. Arch. Ophthalmol. (2008) (In Press).
57. Inagaki Y, Mashima Y, Fuse N et al.: Polymorphism of β-adrenergic receptors and susceptibility to open-angle glaucoma. Mol. Vis. 12, 673-680 (2006).
58. Gungor K, Beydagi H, Bekir N et al.: The impact of acute dynamic exercise on intraocular pressure: role of the β 2-adrenergic receptor polymorphism. J. Int. Med. Res. 30, 26-33 (2002).
59. McLaren N, Reed DM, Musch DC et al.: Evaluation of the β2-adrenergic receptor gene as a candidate glaucoma gene in 2 ancestral populations. Arch. Ophthalmol. 125, 105-111 (2007).
60. Kirchheiner J, Heesch C, Bauer S et al.: Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 76, 302-312 (2004).
61. Rau T, Heide R, Bergmann K et al.: Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 12, 465-472 (2002).
62. Edeki TI, He H, Wood AJ: Pharmacogenetic explanation for excessive β-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. JAMA 274, 1611-1613 (1995).
63. Quigley HA, Broman AT: The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Opthalmol. 90, 262-267 (2006).
64. Wilke RA, Reif DG, Moore JH: Combinatorial pharmacogenetics. Nat. Rev. Drug Discov. 4, 911-918 (2005).
65. Wilke RA, Mareedu R, Moore JH: The pathway less traveled: moving toward candidate genes and candidate pathways in the analysis of genome wide data from large-scale pharmacogenetic association studies. Curr. Pharmacogenomics Personalized Med. (2008) (In Press).